- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05868967
A Clinical Study to Investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects
May 11, 2023 updated by: Daewoong Pharmaceutical Co. LTD.
The purpose of this study is to investigate the Mass Balance and Biotransformation of [14C]DWP14012 in Healthy Chinese Male Subjects
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a single-center, single-dose, non-randomized, open-label design with two parts.
Each subject will receive a single oral dose of [14C]DWP14012 suspension (containing approximately 40 mg/80 μCi [14C]DWP14012) under the fasting conditions
Study Type
Interventional
Enrollment (Anticipated)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing GoBroad Boren Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Healthy male subjects aged 18 to 45 years (including boundary values);
- Body weight ≥ 50.0 kg and body mass index (BMI) between 19.0 and 26.0 kg/m2 (including boundary values);
- Subjects must give informed consent to this study before the study and voluntarily sign a written informed consent form;
- Have no plan for fertility/sperm donation during the study and within 1 year after completion of the study, and take strict contraceptive measures with their spouses (see Appendix 3 for details);
- Have good hygiene habits, and are able to communicate well with the investigator and complete the study in accordance with the study regulations.
Exclusion Criteria:
- Subjects with an allergic constitution, including those with a history of drug allergy or allergic reactions and are known to be allergic to this product or other P-CABs, PPIs or other drugs (e.g., aspirin and antibiotics); and those who are allergic to any food ingredients or have special requirements for diet and unable to take the unified diet;
- Subjects with clinically significant abnormalities or medical history of hepatic, renal, gastrointestinal, neurological, respiratory, endocrine, hematological, oncological, cardiovascular, urological, or psychiatric disorders;
- Subjects with abnormal and clinically significant results of vital signs, physical examination, laboratory tests (hematology, blood chemistry, urinalysis, coagulation function, thyroid functions (FT3, FT4, TSH), stool routine + occult blood), 12-lead electrocardiogram, abdominal B-ultrasound (hepatobiliary, pancreas, spleen and kidney) as judged by the investigator;
- Subjects who are positive for any one of the hepatitis B surface antigen, hepatitis C antibody, treponema pallidum antibody, and HIV antigen/antibody combination test (primary screening);
- Subjects with any medical condition that, in the opinion of the investigator, may increase the risk during the subject's participation in this study (especially a history of esophageal or gastrointestinal ulcers), may interfere with drug absorption, distribution, metabolism or excretion, or may impair protocol compliance;
- Subjects with frequent alcohol consumption within 6 months prior to screening, i.e., more than 14 units of alcohol per week (1 unit = 285 mL of beer or 25 mL of spirits containing 40% alcohol or 100 mL of wine); or alcoholics; or those with a positive alcohol breath test at screening and baseline admission;
- Subjects who have smoked more than 5 cigarettes per day or habitually used nicotine-containing products within 3 months before screening and are unable to withdraw during the study;
- Subjects who have used soft drugs (e.g., cannabis) within 3 months before screening or hard drugs (e.g., cocaine, amphetamines, phencyclidine, etc.) within 1 year before screening; or have a history of drug abuse; or have a positive urine drug test at screening and baseline admission;
- Subjects who have taken any investigational product or participated in any clinical trial of drugs within 3 months prior to screening;
- Subjects who have participated in blood donation within 3 months prior to screening with a total blood donation of ≥ 400 mL or total blood loss of ≥ 400 mL, or who have participated in blood donation within one month prior to screening with a total blood donation of ≥ 200 mL or total blood loss of ≥ 200 mL; or who have received blood transfusion; or who plan to donate blood within 1 month after the end of this study;
- Subjects who have used any medication that alters liver enzyme activity within 4 weeks prior to dosing (see Appendix 1 for details);
- Subjects who have used any prescription or over-the-counter drugs, any vitamin products, health care drugs or Chinese herbal medicines within 14 days prior to dosing;
- Subjects who have habitual consumption of grapefruit juice or excessive amounts of tea, coffee and/or caffeine-containing beverages, and are unable to withdraw during the study;
- Subjects with a history of fear of needles and hemophobia, difficulty in blood collection or intolerance to venipuncture blood collection; radiopharmaceutical labeling studies;
- Subjects whose work requires long-term exposure to radioactive conditions; or who have significant radioactive exposure (≥ 2 chest/ abdominal CTs, or ≥ 3 other types of X-rays) within 1 year prior to screening; or who have participated in radiopharmaceutical labeling studies;
- Subjects with other factors that are not suitable for participation in this study as judged by the investigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: [14C]DWP14012
Type: [14C]DWP14012 suspension containing 40 mg/80 μCi Dosage: orally take the suspension
|
Each subject will receive a single oral dose of [14C]DWP14012 suspension (containing approximately 40 mg/80 μCi [14C]DWP14012) under fasting conditions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tmax
Time Frame: Up to 168hours(approx) from administration
|
Time to peak Concentration
|
Up to 168hours(approx) from administration
|
Cmax
Time Frame: Up to 168hours(approx) from administration
|
Maximum Concentration
|
Up to 168hours(approx) from administration
|
AUC0-t
Time Frame: Up to 168hours(approx) from administration
|
Area under the plasma concentraion-time curve
|
Up to 168hours(approx) from administration
|
AUC0-∞
Time Frame: Up to 168hours(approx) from administration
|
Area under the curve from time 0 extrapolated to infinite time
|
Up to 168hours(approx) from administration
|
t1/2
Time Frame: Up to 168hours(approx) from administration
|
Elimination Phase Half-life
|
Up to 168hours(approx) from administration
|
MRT
Time Frame: Up to 168hours(approx) from administration
|
Mean Residence Time
|
Up to 168hours(approx) from administration
|
CL/F
Time Frame: Up to 168hours(approx) from administration
|
apparent oral clearnace
|
Up to 168hours(approx) from administration
|
Vd/F
Time Frame: Up to 168hours(approx) from administration
|
apparent oral volume of distribution
|
Up to 168hours(approx) from administration
|
Ratio of total radioactivity in whole blood/plasma
Time Frame: Up to 168hours(approx) from administration
|
Total measured radioactivity content of urine and fecal samples collected at each sampling interval
|
Up to 168hours(approx) from administration
|
Cumulative recovery of total radioactive substances
Time Frame: Up to 168hours(approx) from administration
|
Measurement of cumulative recovery ratio in urine or/and feces to meet the criteria for termination
|
Up to 168hours(approx) from administration
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To observe the safety of [14C]DWP14012
Time Frame: Up to study completion, approximately up to 2000 hours
|
Adverse events, serious adverse events etc.
|
Up to study completion, approximately up to 2000 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Fang Hou, Beijing GoBroad Boren Hospital
- Principal Investigator: Wel Tan, Beijing GoBroad Boren Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 27, 2023
Primary Completion (Anticipated)
May 31, 2023
Study Completion (Anticipated)
October 31, 2023
Study Registration Dates
First Submitted
April 7, 2023
First Submitted That Met QC Criteria
May 11, 2023
First Posted (Actual)
May 22, 2023
Study Record Updates
Last Update Posted (Actual)
May 22, 2023
Last Update Submitted That Met QC Criteria
May 11, 2023
Last Verified
April 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- DW_DWP14012112
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phase 1 Study, Healthy Volunteers
-
Daewoong Pharmaceutical Co. LTD.CompletedPhase 1 Study, Healthy VolunteersKorea, Republic of
-
Isofol Medical ABCompletedPhase I Study in Healthy Volunteers to Evaluate ECG EffectSweden
-
Tarsa Therapeutics, Inc.CompletedPhase 1 Pharmacodynamic StudyUnited States
-
Atea Pharmaceuticals, Inc.Hoffmann-La RocheCompleted
-
University of KarachiCenter for Bioequivalence Studies and Clinical Research; Merck Pvt. Ltd, PakistanCompletedHealthy Volunteers | Bioequivalence StudyPakistan
-
AstraZenecaCompletedHealthy Volunteers Bioavailability StudyUnited Kingdom
-
AstraZenecaCompletedHealthy Volunteers Pharmacokinetic StudyUnited Kingdom
-
University of KarachiCenter for Bioequivalence Studies and Clinical Research; Merck Pvt. Ltd, PakistanCompletedHealthy Volunteers | Bioequivalence StudyPakistan
-
University Medicine GreifswaldCompletedImpact of OCT1 and CYP2D6 Genotypes on Pharmacokinetics of Berberine in Healthy Volunteers (BERKI-1)Pharmacokinetic Study in Healthy VolunteersGermany
-
University Medicine GreifswaldNot yet recruitingPharmacokinetic Study in Healthy VolunteersGermany
Clinical Trials on [14C]DWP14012
-
Daewoong Pharmaceutical Co. LTD.CompletedAcute Gastritis | Chronic GastritisKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedDrug-drug InteractionAustralia
-
Daewoong Pharmaceutical Co. LTD.CompletedPhase 1 Study, Healthy VolunteersKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthyKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthyKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthyKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.UnknownNon-Erosive Gastroesophageal Reflux DiseaseKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.CompletedHealthy VolunteersKorea, Republic of
-
Daewoong Pharmaceutical Co. LTD.RecruitingNon-erosive Reflux Disease | Non-Erosive Gastro-Esophageal Reflux Disease | Non-Erosive Esophageal Reflux DiseaseKorea, Republic of
-
Konkuk University Medical CenterDaewoong Pharmaceutical Co. LTD.RecruitingErosive EsophagitisKorea, Republic of